Clinical trial
Safety and Efficacy of Ripertamab in Generalized Myasthenia Gravis
NCT07372807 is registered in ClinicalTrials.gov with Zhongming Qiu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Ripertamab in Generalized Myasthenia Gravis
- Lead sponsor
- Zhongming Qiu
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- February 28, 2026
- Completion date
- December 31, 2027
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
myasthenia gravis (mg)